Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

The final barrier is trust, and we can’t build it without education and advocacy Even if we have the right policies and systems in place, biosimilar medicines can only deliver their full impact ...

They worry tariffs, aimed at bringing drug production to the United States, could instead drive companies out of business ...

The layoffs will take effect on July 22 and particularly target those working in sales, data engineering and product ...

The IP team at Morais Leitão discusses high-stakes litigation, strategic partnerships with clients, and bolstering ...

a lack of physician education has been one of the reasons biosimilar uptake has been slower in the US. Manufacturers can work with a commercialisation partner to build provider confidence through ...

The pharmaceutical company is evaluating all options to increase its presence in therapy areas, including in-licensing ...

Apple tops our list of the stocks that the best fund managers are selling, yet it remains a widely held stock among these ...

Adar Poonawalla, CEO, Serum Institute of India, on life after Covid, vaccine pricing, and expansion into new frontiers.